These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Novel influenza vaccine M2SR protects against drifted H1N1 and H3N2 influenza virus challenge in ferrets with pre-existing immunity. Hatta Y; Boltz D; Sarawar S; Kawaoka Y; Neumann G; Bilsel P Vaccine; 2018 Aug; 36(33):5097-5103. PubMed ID: 30007825 [TBL] [Abstract][Full Text] [Related]
8. Intranasal booster using an Omicron vaccine confers broad mucosal and systemic immunity against SARS-CoV-2 variants. Wang Q; Yang C; Yin L; Sun J; Wang W; Li H; Zhang Z; Chen S; Liu B; Liu Z; Shi L; Liu X; Guan S; Wang C; Qu L; Feng Y; Niu X; Feng L; Zhao J; Li P; Chen L; Zhong N Signal Transduct Target Ther; 2023 Apr; 8(1):167. PubMed ID: 37069171 [TBL] [Abstract][Full Text] [Related]
9. Intranasal M2SR (M2-deficient Single Replication) Influenza Vaccine Induces Broadly Reactive Mucosal Antibody Production in Adults. Hill-Batorski L; Weiner JA; Ackerman ME; Hatta Y; Hoft DF; Herber R; Moser MJ; Bilsel P J Infect Dis; 2024 Jul; ():. PubMed ID: 39012796 [TBL] [Abstract][Full Text] [Related]
14. An intranasal influenza virus-vectored vaccine prevents SARS-CoV-2 replication in respiratory tissues of mice and hamsters. Deng S; Liu Y; Tam RC; Chen P; Zhang AJ; Mok BW; Long T; Kukic A; Zhou R; Xu H; Song W; Chan JF; To KK; Chen Z; Yuen KY; Wang P; Chen H Nat Commun; 2023 Apr; 14(1):2081. PubMed ID: 37045873 [TBL] [Abstract][Full Text] [Related]
15. Enhanced mucosal immune responses and reduced viral load in the respiratory tract of ferrets to intranasal lipid nanoparticle-based SARS-CoV-2 proteins and mRNA vaccines. Boley PA; Lee CM; Schrock J; Yadav KK; Patil V; Suresh R; Lu S; Feng MM; Hanson J; Channappanavar R; Kenney SP; Renukaradhya GJ J Nanobiotechnology; 2023 Feb; 21(1):60. PubMed ID: 36814238 [TBL] [Abstract][Full Text] [Related]
16. Mucosal immunization with Ad5-based vaccines protects Syrian hamsters from challenge with omicron and delta variants of SARS-CoV-2. Braun MR; Martinez CI; Dora EG; Showalter LJ; Mercedes AR; Tucker SN Front Immunol; 2023; 14():1086035. PubMed ID: 36911687 [TBL] [Abstract][Full Text] [Related]
17. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection. Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290 [TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Zhu F; Zhuang C; Chu K; Zhang L; Zhao H; Huang S; Su Y; Lin H; Yang C; Jiang H; Zang X; Liu D; Pan H; Hu Y; Liu X; Chen Q; Song Q; Quan J; Huang Z; Zhong G; Chen J; Han J; Sun H; Cui L; Li J; Chen Y; Zhang T; Ye X; Li C; Wu T; Zhang J; Xia NS Lancet Respir Med; 2022 Aug; 10(8):749-760. PubMed ID: 35644168 [TBL] [Abstract][Full Text] [Related]
19. Characterization of Systemic and Mucosal Humoral Immune Responses to an Adjuvanted Intranasal SARS-CoV-2 Protein Subunit Vaccine Candidate in Mice. Maltseva M; Galipeau Y; Renner TM; Deschatelets L; Durocher Y; Akache B; Langlois MA Vaccines (Basel); 2022 Dec; 11(1):. PubMed ID: 36679875 [TBL] [Abstract][Full Text] [Related]
20. Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection. Du L; Zhao G; Lin Y; Sui H; Chan C; Ma S; He Y; Jiang S; Wu C; Yuen KY; Jin DY; Zhou Y; Zheng BJ J Immunol; 2008 Jan; 180(2):948-56. PubMed ID: 18178835 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]